Across TCGA pan-cancer cohorts, PPARA Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PPARA data layer compared with 24 for mass-spec protein.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher PPARA Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PPARA expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

CESC, UCEC, and LIHC are the cancer types where PPARA Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	OS	Median	II,III,IV	0.047	0.830	<.001	12	view →
UCEC	OS	Median	IV	0.346	0.764	<.001	6	view →
LIHC	OS	Median	III,IV	0.119	0.535	.035	6	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →
SKCM	OS	Median	All	0.741	0.328	.048	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: PPARA tumor-vs-normal RNA expression · all PPARA data types